Rapport Therapeutics (RAPP) CFO Ignelzi Buys $144K of Stock
Key Points
- Chief Financial Officer Troy A. Ignelzi bought 5,500 shares of Rapport Therapeutics on October 21, 2026, at a price of $26.10 per share for a total value of $143,550.
- After the trade, Troy A. Ignelzi holds 15,500 $RAPP shares, up 55% from before the trade.
- Major institutional holders adjusted stakes earlier in the year, with Trv Gp V, LLC reducing holdings by 854,814 shares to 6,280,525 shares worth $157,389,953.
- Wall Street firms recently updated their views, including Jones Trading maintaining a buy rating and raising its target to $82.00 on October 21, 2026.
Get Rapport Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $RAPP.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Rapport Therapeutics, Inc. alert may contain errors. Disclosures
Chief Financial Officer Troy A. Ignelzi bought 5,500 shares of Rapport Therapeutics, Inc. (NasdaqGM: RAPP) on October 21, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the purchase totaled $143,550 at a price of $26.10 per share.
RAPP
Rapport Therapeutics, Inc.
Troy A. Ignelzi vs. the S&P 500
Hypothetical returns from Troy A. Ignelzi's disclosed trades, not real profit or advice. How we model this.
Inside Troy A. Ignelzi's Rapport Therapeutics Trade
The open-market purchase increased the CFO's direct holdings by 55.0% to a total of 15,500 shares. The trade was not executed under a pre-arranged Rule 10b5-1 trading plan. Rapport Therapeutics closed at $27.57 on October 16, 2026, and the stock recently traded around $29.37 as of October 21, 2026, putting it up about 6.5% since that close.
Other Institutional Activity in Rapport Therapeutics
Trv Gp V, LLC grew its holdings by -854814 shares, ending with 6,280,525 shares worth about $157,389,953. Arch Venture Management, Llc held steady with 3,728,738 shares valued at $93,442,172. Capital International Investors reduced its holdings by 175,962 shares, ending with 2,921,958 shares worth about $73,224,265. Cormorant Asset Management, LP trimmed its stake by 299,881 shares to 2,657,521 shares valued at $66,597,474. Sofinnova Investments, Inc. kept its position unchanged at 1,904,408 shares worth about $47,724,463.
Rapport Therapeutics, Inc. Stock Down 27.4%
The stock recently traded around $29.37 on October 21, 2026, sitting above the $27.57 close recorded on October 16, 2026.
Recent Earnings
The company reported trailing-twelve-month revenue of $20.0 million and an EPS of -$3.03. Its next earnings release is scheduled for November 5, 2026.
Insider Buying and Selling at Rapport Therapeutics, Inc.
Chief Executive Officer Abraham N Ceesay disposed of 8,210 shares on September 8, 2026, for $374,498, followed by a sale of 2,210 shares for $86,268 on September 23, 2026, and another sale of 4,522 shares for $143,273 on October 7, 2026. Chief Operating Officer Cheryl Gault sold 10,000 shares on September 30, 2026, for $331,856.
Analysts Set New Price Targets
HC Wainwright & Co. reiterated a buy rating with a $66.00 price target on October 20, 2026. BTIG maintained a buy rating and raised its target from $75.00 to $89.00 on October 20, 2026. Jones Trading maintained a buy rating while lifting its target to $82.00 from $50.00 on October 21, 2026. Wells Fargo maintained an overweight rating with a target of $50.00 down from $51.00 on October 21, 2026. Guggenheim maintained a buy rating with a target of $70.00 up from $65.00 on October 21, 2026.
About Rapport Therapeutics
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The company focuses on discovering and developing transformational small molecule medicines for patients suffering from central nervous system disorders.
Bottom Line
Investors will watch the upcoming earnings release on November 5, 2026, for further updates on the company's clinical pipeline and financial progress.
Related Filing Alerts
Source: Troy A. Ignelzi's Form 4 filing on $RAPP (Oct 21, 2026). Written by software, not financial advice. How we make alerts